Clemastine
Tavist (clemastine) is a small molecule pharmaceutical. Clemastine was first approved as Tavist on 1982-01-01. It is used to treat allergic rhinitis perennial, angioedema, and urticaria in the USA. The pharmaceutical is active against histamine H1 receptor. In addition, it is known to target P2X purinoceptor 7.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Acetaminophen
+
Clemastine fumarate
+
Pseudoephedrine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TAVIST ALLERGY/SINUS/HEADACHE | Novartis | N-021082 DISCN | 2001-03-01 | 1 products |
Hide discontinued
Clemastine fumarate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TAVIST-1 | GSK | N-020925 DISCN | 1992-08-21 | 1 products, RLD |
| TAVIST-1 | Novartis | N-017661 DISCN | 1992-08-21 | 1 products |
| TAVIST | Novartis | N-017661 DISCN | 1982-01-01 | 1 products, RLD |
| TAVIST-1 | Novartis | N-017661 DISCN | 1982-01-01 | 1 products |
| TAVIST | Novartis | N-018675 DISCN | 1985-06-28 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| clemastine fumarate | ANDA | 2022-10-19 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| allergic rhinitis perennial | EFO_1001417 | D012221 | J30.89 |
| angioedema | EFO_0005532 | D000799 | T78.3 |
| urticaria | EFO_0005531 | D014581 | L50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D04: Antipruritics, incl. antihistamines, anesthetics, etc.
— D04A: Antipruritics, incl. antihistamines, anesthetics, etc.
— D04AA: Antihistamines for topical use
— D04AA14: Clemastine
R: Respiratory system drugs
— R06: Antihistamines for systemic use
— R06A: Antihistamines for systemic use
— R06AA: Aminoalkyl ethers, systemic antihistamines
— R06AA04: Clemastine
— R06AA54: Clemastine, combinations
HCPCS
No data
Clinical
Clinical Trials
187 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | 1 | 4 | 4 | 5 | 3 | 15 | |
| Sinusitis | D012852 | EFO_0007486 | J32 | — | — | 1 | 6 | 5 | 12 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 2 | 5 | 4 | — | 10 |
| Appendicitis | D001064 | EFO_0007149 | K37 | — | — | 1 | 2 | 5 | 8 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | 5 | 1 | — | 6 |
| Wound infection | D014946 | — | — | 1 | 3 | — | 4 | ||
| Respiratory tract infections | D012141 | J06.9 | 2 | — | 1 | 1 | — | 4 | |
| Surgical wound infection | D013530 | — | — | — | 2 | 2 | 4 | ||
| Chronic bronchitis | D029481 | J42 | — | — | 1 | 1 | 1 | 3 | |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | — | 2 | 1 | — | 3 |
Show 27 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | 1 | 1 | — | — | 2 |
| Intraabdominal infections | D059413 | — | — | 2 | — | — | 2 | ||
| Diabetic foot | D017719 | EFO_1001459 | — | — | 1 | — | 1 | 2 | |
| Febrile neutropenia | D064147 | — | — | 2 | — | — | 2 | ||
| Neutropenia | D009503 | D70 | — | — | 1 | — | 1 | 2 | |
| Neoplasms | D009369 | C80 | — | — | 1 | — | 1 | 2 | |
| Lymphoma | D008223 | C85.9 | — | — | 1 | — | 1 | 2 | |
| Bronchitis | D001991 | J40 | — | — | 1 | — | — | 1 | |
| Abscess | D000038 | EFO_0003030 | — | — | 1 | — | — | 1 | |
| Ulcer | D014456 | MPATH_579 | — | — | 1 | — | — | 1 |
Show 22 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | 5 | — | — | — | 5 |
| Cocaine-related disorders | D019970 | F14 | 3 | 1 | — | — | — | 4 | |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 1 | 1 | — | — | — | 2 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 2 | — | — | — | 2 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | 1 | — | — | 1 | 2 |
| Asthma | D001249 | EFO_0000270 | J45 | — | 1 | — | — | — | 1 |
| Pelvic infection | D034161 | — | 1 | — | — | — | 1 | ||
| Tobacco use disorder | D014029 | F17 | — | 1 | — | — | — | 1 | |
| Tonsillectomy | D014068 | 1 | 1 | — | — | — | 1 | ||
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 1 | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | — | — | 2 | 2 | ||
| Thyroid nodule | D016606 | EFO_1001436 | — | — | — | — | 2 | 2 | |
| Periapical periodontitis | D010485 | EFO_1001391 | K04.5 | — | — | — | — | 2 | 2 |
| Bisphosphonate-associated osteonecrosis of the jaw | D059266 | — | — | — | — | 1 | 1 | ||
| Peritonsillar abscess | D000039 | EFO_0007429 | J36 | — | — | — | — | 1 | 1 |
| Chemical and drug induced liver injury | D056486 | — | — | — | — | 1 | 1 | ||
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | — | — | — | 1 | 1 |
| Leukemia | D007938 | C95 | — | — | — | — | 1 | 1 | |
| Myelodysplastic syndromes | D009190 | D46 | — | — | — | — | 1 | 1 | |
| Myeloproliferative disorders | D009196 | D47.1 | — | — | — | — | 1 | 1 |
Show 11 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CLEMASTINE |
| INN | clemastine |
| Description | Clemastine is 2-[(2R)-1-Methylpyrrolidin-2-yl]ethanol in which the hydrogen of the hydroxy group is substituted by a 1-(4-chlorophenyl)-1-phenylethyl group (R configuration). An antihistamine with antimuscarinic and moderate sedative properties, it is used as its fumarate salt for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions. It has a role as a H1-receptor antagonist, an anti-allergic agent, a muscarinic antagonist and an antipruritic drug. It is a N-alkylpyrrolidine and a member of monochlorobenzenes. |
| Classification | Small molecule |
| Drug class | antihistaminics (histamine-H1 receptor antagonists) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 15686-51-8 |
| RxCUI | 2578 |
| ChEMBL ID | CHEMBL1626 |
| ChEBI ID | 3738 |
| PubChem CID | 26987 |
| DrugBank | DB00283 |
| UNII ID | 95QN29S1ID (ChemIDplus, GSRS) |
Target
Alternate
P2RX7
P2RX7
Organism
Homo sapiens
Gene name
P2RX7
Gene synonyms
NCBI Gene ID
Protein name
P2X purinoceptor 7
Protein synonyms
ATP receptor, P2X7 receptor, P2Z receptor, Purinergic receptor, purinergic receptor P2X, ligand gated ion channel, 7, purnergic receptor P2X 7
Uniprot ID
Mouse ortholog
P2rx7 (18439)
P2X purinoceptor 7 (Q9Z1M0)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,417 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
20,570 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more